Cipla Limited (NSE:CIPLA)
1,343.90
-12.50 (-0.92%)
At close: Feb 17, 2026
Cipla Revenue
Cipla had revenue of 69.63B INR in the quarter ending December 31, 2025, with 0.02% growth. This brings the company's revenue in the last twelve months to 279.67B, up 4.67% year-over-year. In the fiscal year ending March 31, 2025, Cipla had annual revenue of 272.67B with 6.78% growth.
Revenue (ttm)
279.67B
Revenue Growth
+4.67%
P/S Ratio
3.88
Revenue / Employee
9.23M
Employees
30,313
Market Cap
1.09T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 568.09B |
| Aurobindo Pharma | 331.82B |
| Zydus Lifesciences | 260.89B |
| Glenmark Pharmaceuticals | 165.10B |
| Alkem Laboratories | 142.53B |
| Mankind Pharma | 139.14B |
| Divi's Laboratories | 103.14B |
| Ipca Laboratories | 95.06B |
Cipla News
- 5 days ago - Nifty 50 top losers today, Feb 12: Cipla, Adani Enterprises, Maruti Suzuki India, INDIGO, Adani Ports and more - Business Upturn
- 12 days ago - Cipla Launches Win Over Weight Campaign, Igniting a National Conversation on Obesity Care in India - Business Upturn
- 15 days ago - Nifty 50 top losers today, Feb 2: Shriram Finance, Axis Bank, Max Healthcare, Infosys, Cipla and more - Business Upturn
- 15 days ago - Top losers among Nifty 50 stocks in midday trade today, Feb 2: Shriram Finance, Cipla, Trent, Infosys, Axis Bank and more - Business Upturn
- 15 days ago - Pharma sector stocks today, Feb 2: Cipla down 2%, Lupin falls 1.72%, Torrent Pharma drops 1.92% - Business Upturn
- 22 days ago - Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues - NDTV
- 25 days ago - Cipla Ltd (BOM:500087) Q3 2026 Earnings Call Highlights: Strategic Growth Amidst Margin Challenges - GuruFocus
- 25 days ago - Q3 2026 Cipla Ltd Earnings Call Transcript - GuruFocus